<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618600</url>
  </required_header>
  <id_info>
    <org_study_id>ScrippsTSI</org_study_id>
    <nct_id>NCT05618600</nct_id>
  </id_info>
  <brief_title>Scripps-eMed Covid-19 Study: A Prospective Monitoring Study for Those Individuals Treated With Paxlovid</brief_title>
  <official_title>Scripps-eMed Covid-19 Study: A Prospective Monitoring Study for Those Individuals Treated With Paxlovid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>eMed</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Scripps Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective monitoring study for those individuals treated with Paxlovid&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to understand the epidemiology and pathophysiology of Paxlovid&#xD;
      rebound in patients with acute Covid-19 infection who have been prescribed the Paxlovid per&#xD;
      standard of care.&#xD;
&#xD;
      The study will be a collaborative effort between Scripps and eMed, digitally recruiting 800&#xD;
      participants who have tested positive for Covid-19 and have agreed to be prescribed Paxlovid&#xD;
      on the eMed platform.&#xD;
&#xD;
      The vision of the study is to understand Paxlovid rebound and ultimately inform management of&#xD;
      acute Covid-19 infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 4, 2022</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Paxlovid Rebound</measure>
    <time_frame>16 day period</time_frame>
    <description>Incidence of paxlovid rebound defined as test positivity after a documented negative rapid antigen test post 5 day course of Paxlovid</description>
  </primary_outcome>
  <other_outcome>
    <measure>Symptomatology long term</measure>
    <time_frame>6 month period</time_frame>
    <description>Understand the long term impact of paxlovid rebound on symptomatology</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of viral rebound</measure>
    <time_frame>16 day period</time_frame>
    <description>Differences in viral rebound between control and paxlovid group</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of grouped symptomatology</measure>
    <time_frame>16 day period</time_frame>
    <description>Differences in symptomatology between control and paxlovid group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immune profile</measure>
    <time_frame>6 month period</time_frame>
    <description>Differences in immune profile between control and paxlovid group</description>
  </other_outcome>
  <other_outcome>
    <measure>Viral Evolution</measure>
    <time_frame>6 month period</time_frame>
    <description>Differences in viral evolution between control and paxlovid group</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Paxlovid Cohort</arm_group_label>
    <description>Participants will be separated into 2 arms that are self-selected through the decision to opt in or out of Paxlovid. After patients are offered a 5-day course of Paxlovid and have made a treatment decision they will be eligible to join the study. Arm 1 will include 400 participants that opt to take the 5-day course of Paxlovid. Participation will look identical in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Cohort</arm_group_label>
    <description>Participants will be separated into 2 arms that are self-selected through the decision to opt in or out of Paxlovid. After patients are offered a 5-day course of Paxlovid and have made a treatment decision they will be eligible to join the study. Arm 2, control, will include 400 participants that opt out of taking the 5-day course of Paxlovid. Participation will look identical in this study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be obtained from the eMed platform and will consist of&#xD;
        participants that tested positive using an eMed rapid antigen test, who underwent a&#xD;
        telemedicine visit and opted in or out of receiving a prescription for a 5-day course of&#xD;
        Paxlovid.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Covid positive&#xD;
&#xD;
          -  Qualified for Paxlovid prescription (treatment decision already made prior to&#xD;
             enrollment)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-english speaking&#xD;
&#xD;
          -  Resides outside of the United States&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Pandit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Research Institute</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 11, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scripps Translational Science Institute</investigator_affiliation>
    <investigator_full_name>Jay Pandit</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Paxlovid</keyword>
  <keyword>Rebound</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

